Literature DB >> 8662854

Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras.

B P Monia1, J F Johnston, H Sasmor, L L Cummins.   

Abstract

We have previously described structure-activity studies on a 17-mer uniform phosphorothioate antisense sequence targeted to human Ha-ras. In an effort to further improve the pharmacological properties of antisense oligonucleotides, structure-activity studies on this 17-mer sequence were expanded to examine both the effects of replacing phosphorothioate backbone linkages with phosphodiester linkages and the effects of incorporating various 2'-sugar modifications into phosphorothioate and phosphodiester oligonucleotides on oligonucleotide stability against nucleases in vitro and on antisense activity in cells. Replacement of three or more phosphorothioate linkages with phosphodiester linkages greatly compromised both nuclease resistance and antisense activity, and these effects correlated directly with the number of phosphodiester linkages incorporated into the oligonucleotide. However, substantial nuclease resistance, sufficient for obtaining potent antisense effects in cells, was conferred to phosphodiester oligonucleotides by incorporation of appropriate 2'-alkoxy sugar modifications. Nuclease stability and antisense activity imparted by these sugar modifications in phosphodiester backbones correlated with the size of the 2'-alkoxy substituent (pentoxy > propoxy > methoxy > deoxy). Furthermore, antisense activity mediated by oligonucleotides that exhibit partial resistance to nucleolytic degradation was dependent on both oligonucleotide concentration and the duration of oligonucleotide treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662854     DOI: 10.1074/jbc.271.24.14533

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.

Authors:  P Lorenz; T Misteli; B F Baker; C F Bennett; D L Spector
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

Review 2.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

Review 3.  Antisense technology: an overview and prospectus.

Authors:  Stanley T Crooke; Brenda F Baker; Rosanne M Crooke; Xue-Hai Liang
Journal:  Nat Rev Drug Discov       Date:  2021-03-24       Impact factor: 84.694

Review 4.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

5.  RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.

Authors:  Johanna E Lee; C Frank Bennett; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

6.  HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.

Authors:  Miki Watanabe; Sulaiman Sheriff; Kenneth B Lewis; Stuart L Tinch; Junho Cho; Ambikaipakan Balasubramaniam; Michael A Kennedy
Journal:  Cancer Lett       Date:  2011-10-10       Impact factor: 8.679

Review 7.  Canonical and non-canonical barriers facing antimiR cancer therapeutics.

Authors:  Christopher J Cheng; W Mark Saltzman; Frank J Slack
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

8.  Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.

Authors:  R V Giles; D G Spiller; J Grzybowski; R E Clark; P Nicklin; D M Tidd
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

9.  Chimeric RNase H-competent oligonucleotides directed to the HIV-1 Rev response element.

Authors:  Chrissy E Prater; Anthony D Saleh; Maggie P Wear; Paul S Miller
Journal:  Bioorg Med Chem       Date:  2007-06-02       Impact factor: 3.641

10.  Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS).

Authors:  David H Dreyfus; S Mark Tompkins; Ramsay Fuleihan; Lucy Y Ghoda
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.